OK Clinical Research, LLC

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Migraine6 trials
• Asthma3 trials

Phase

• Phase 26 trials
• Phase 32 trials
• Phase 41 trial

Status

• Completed4 trials
• Recruiting2 trials
• Terminated2 trials
• Active, not recruiting1 trial

Lead sponsor

• TriGemX Bio, Inc.4 trials
• Upstream Bio Inc.2 trials
• Biohaven Therapeutics Ltd.1 trial
• Pfizer1 trial
• RAPT Therapeutics, Inc., a member of the GSK plc group of companies1 trial

Running trials

• Recruiting

  A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

  NCT07674654· Phase 3· TriGemX Bio, Inc.· Source

  Contact: Annemarie Vance

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

  NCT07645924· Phase 3· TriGemX Bio, Inc.· Source

  Contact: Annemarie Vance

• Active, not recruiting

  A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)

  NCT06966479· Phase 2· Upstream Bio Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Migraine2 recruiting

Closed trials

• Terminated

  A Study of K-645 in the Treatment of Multiple Migraine Attacks

  NCT07116499· Phase 2· TriGemX Bio, Inc.· Source

• Completed

  A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine

  NCT06848075· Phase 2· TriGemX Bio, Inc.· Source

• Completed

  Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine

  NCT06603623· Phase 2· Biohaven Therapeutics Ltd.· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)

  NCT06196879· Phase 2· Upstream Bio Inc.· Source

• Terminated

  Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma

  NCT05935332· Phase 2· RAPT Therapeutics, Inc., a member of the GSK plc group of companies· Source

• Completed

  Safety and Tolerability Study of Daily Dosing Rimegepant in Episodic Migraine Prevention

  NCT05207865· Phase 4· Pfizer· Source